• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

终末期肾病相关血管钙化中血清磷酸盐及相关因素的关联

Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification.

作者信息

Zheng Cai-Mei, Lu Kuo-Cheng, Wu Chia-Chao, Hsu Yung-Ho, Lin Yuh-Feng

机构信息

Division of Nephrology, Department of Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, Taipei 235, Taiwan.

出版信息

Int J Nephrol. 2011;2011:939613. doi: 10.4061/2011/939613. Epub 2011 May 25.

DOI:10.4061/2011/939613
PMID:21660259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3108197/
Abstract

Vascular calcification is common in ESRD patients and is important in increasing mortality from cardiovascular complications in these patients. Hyperphosphatemia related to chronic kidney disease is increasingly known as major stimulus for vascular calcification. Hyperphosphatemia and vascular calcification become popular discussion among nephrologist environment more than five decades, and many researches have been evolved. Risk factors for calcification are nowadays focused for the therapeutic prevention of vascular calcification with the hope of reducing cardiovascular complications.

摘要

血管钙化在终末期肾病患者中很常见，并且在增加这些患者心血管并发症导致的死亡率方面具有重要意义。与慢性肾病相关的高磷血症日益被认为是血管钙化的主要刺激因素。高磷血症和血管钙化在肾脏病学领域已经成为热门讨论话题五十多年了，并且已经开展了许多研究。如今，钙化的危险因素聚焦于血管钙化的治疗性预防，以期降低心血管并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15bc/3108197/373659a67ee8/IJN2011-939613.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15bc/3108197/373659a67ee8/IJN2011-939613.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15bc/3108197/373659a67ee8/IJN2011-939613.001.jpg

相似文献

1
Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification.终末期肾病相关血管钙化中血清磷酸盐及相关因素的关联
Int J Nephrol. 2011;2011:939613. doi: 10.4061/2011/939613. Epub 2011 May 25.
2
Different risk factors for vascular calcification in end-stage renal disease between diabetics and nondiabetics: the respective importance of glycemic and phosphate control.糖尿病患者与非糖尿病患者终末期肾病血管钙化的不同危险因素：血糖控制和磷酸盐控制的各自重要性。
Kidney Blood Press Res. 2008;31(1):10-5. doi: 10.1159/000112542. Epub 2007 Dec 19.
3
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification.镁与抑制血管钙化的临床生物标志物的关系。
Am J Nephrol. 2012;35(1):31-9. doi: 10.1159/000334742. Epub 2011 Dec 15.
4
The emerging role of phosphate in vascular calcification.磷酸盐在血管钙化中的新作用。
Kidney Int. 2009 May;75(9):890-7. doi: 10.1038/ki.2008.644. Epub 2009 Jan 14.
5
Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.肾衰竭患者高磷血症药物治疗的进展
Expert Opin Pharmacother. 2023 Sep-Dec;24(15):1737-1746. doi: 10.1080/14656566.2023.2243817. Epub 2023 Aug 11.
6
lncRNA FAS-AS1 served as a diagnostic biomarker of end-stage renal disease and mediated vascular calcification via regulating oxidative stress and inflammation.lncRNA FAS-AS1 可作为终末期肾病的诊断生物标志物，并通过调节氧化应激和炎症来介导血管钙化。
Gene. 2024 Feb 20;896:148035. doi: 10.1016/j.gene.2023.148035. Epub 2023 Nov 25.
7
Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.终末期肾病患者的心血管钙化：一个百年现象。
Kidney Int Suppl. 2002 Dec(82):S73-80. doi: 10.1046/j.1523-1755.62.s82.15.x.
8
Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.评估接受血液透析患者使用含钙的磷结合剂与心血管钙化相关的发病率和死亡率数据。
Pharmacotherapy. 2010 Jul;30(7):741-8. doi: 10.1592/phco.30.7.741.
9
Pathogenesis and Management of Vascular Calcification in Patients with End-Stage Renal Disease.终末期肾病患者血管钙化的发病机制与管理
Contrib Nephrol. 2018;196:71-77. doi: 10.1159/000485702. Epub 2018 Jul 24.
10
[Roles of hyperphosphatemia in vascular calcification].[高磷血症在血管钙化中的作用]
Clin Calcium. 2009 Feb;19(2):180-5.

引用本文的文献

1
Assessment of Serum Phosphate Levels in Chronic Kidney Disease Patients Across Different Stages of Kidney Disease.评估不同肾病阶段慢性肾病患者的血清磷酸盐水平。
Cureus. 2025 Apr 26;17(4):e83051. doi: 10.7759/cureus.83051. eCollection 2025 Apr.
2
Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.终末期肾病高磷血症患者使用替纳普仑的疗效和安全性：系统评价和荟萃分析。
Ren Fail. 2024 Dec;46(2):2410389. doi: 10.1080/0886022X.2024.2410389. Epub 2024 Oct 1.
3
Association of diabetes with cardiovascular calcification and all-cause mortality in end-stage renal disease in the early stages of hemodialysis: a retrospective cohort study.

本文引用的文献

1
Phosphate and FGF-23.磷酸盐和 FGF-23。
Kidney Int. 2011 Apr;79121:S24-7. doi: 10.1038/ki.2011.27.
2
Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo.线粒体活性氧促进 p65 核转位介导高磷诱导的血管钙化的体外和体内研究。
Kidney Int. 2011 May;79(10):1071-9. doi: 10.1038/ki.2011.18. Epub 2011 Mar 2.
3
Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
糖尿病与血液透析早期终末期肾病患者心血管钙化及全因死亡率的相关性：一项回顾性队列研究。
Cardiovasc Diabetol. 2024 Jul 18;23(1):259. doi: 10.1186/s12933-024-02318-8.
4
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.碳酸司维拉姆与醋酸钙对慢性肾脏病患者血管钙化、炎症和内皮功能障碍的影响。
Clin Transl Sci. 2022 Feb;15(2):353-360. doi: 10.1111/cts.13151. Epub 2021 Oct 2.
5
Kidney-Specific Gene Deletion Causes Aortic Aneurysm via Hyperphosphatemia.肾脏特异性基因缺失通过高磷血症导致主动脉瘤。
Hypertension. 2021 Aug;78(2):308-319. doi: 10.1161/HYPERTENSIONAHA.121.17299. Epub 2021 Jun 28.
6
Progression of Aortic Arch Calcification Is Associated with Overall and Cardiovascular Mortality in Hemodialysis.主动脉弓钙化进展与血液透析患者的全因死亡率和心血管死亡率相关。
Dis Markers. 2020 Jun 20;2020:6293185. doi: 10.1155/2020/6293185. eCollection 2020.
7
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease.破骨细胞释放的 Wnt-10b 是西那卡塞治疗慢性肾脏病骨改善的基础。
Int J Mol Sci. 2019 Jun 8;20(11):2800. doi: 10.3390/ijms20112800.
8
The association between mortality and abdominal aortic calcification and relation between its progression and serum calcium concentration in chronic hemodialysis patients.慢性血液透析患者死亡率与腹主动脉钙化的关系及其进展与血清钙浓度的关系。
Kidney Res Clin Pract. 2014 Jun;33(2):95-102. doi: 10.1016/j.krcp.2014.04.003. Epub 2014 Jun 13.
9
Determinants of coronary artery calcification in maintenance hemodialysis patients.维持性血液透析患者冠状动脉钙化的决定因素
J Artif Organs. 2015 Sep;18(3):251-6. doi: 10.1007/s10047-015-0823-3. Epub 2015 Mar 25.
10
Saliva-based biosensors: noninvasive monitoring tool for clinical diagnostics.基于唾液的生物传感器：用于临床诊断的无创监测工具。
Biomed Res Int. 2014;2014:962903. doi: 10.1155/2014/962903. Epub 2014 Sep 8.
骨化三醇治疗可减轻继发性甲状旁腺功能亢进血液透析患者的炎症和氧化应激。
Tohoku J Exp Med. 2011 Mar;223(3):153-9. doi: 10.1620/tjem.223.153.
4
How KDIGO will (or will not) influence the management of hyperphosphatemia.改善全球肾脏病预后组织（KDIGO）将如何（或不会如何）影响高磷血症的管理。
Semin Dial. 2011 Jan-Feb;24(1):35-6. doi: 10.1111/j.1525-139X.2010.00824.x. Epub 2011 Feb 11.
5
Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release.通过控制骨形态发生蛋白-2 的释放来改善大鼠股骨节段性缺损中的骨形成。
Tissue Eng Part A. 2011 Jul;17(13-14):1735-46. doi: 10.1089/ten.TEA.2010.0446. Epub 2011 Apr 3.
6
Prevention of vascular calcification: is pyrophosphate therapy a solution?防治血管钙化：焦磷酸盐治疗是一种解决方案吗？
Kidney Int. 2011 Mar;79(5):490-3. doi: 10.1038/ki.2010.478.
7
Modeling nucleus pulposus regeneration in vitro: mesenchymal stem cells, alginate beads, hypoxia, bone morphogenetic protein-2, and synthetic peptide B2A.体外模拟髓核再生：间充质干细胞、藻酸盐珠、低氧、骨形态发生蛋白-2 和合成肽 B2A。
Spine (Phila Pa 1976). 2011 Dec 15;36(26):2275-85. doi: 10.1097/BRS.0b013e31820cd1b1.
8
Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?慢性肾脏病矿物质和骨异常（CKD-MBD）中磷潴留/高磷血症的预防和控制：何为正常、何时开始以及如何治疗？
Clin J Am Soc Nephrol. 2011 Feb;6(2):440-6. doi: 10.2215/CJN.05130610. Epub 2011 Feb 3.
9
Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients.骨保护素与2型糖尿病患者的动脉粥样硬化标志物和体脂量相关。
Int J Cardiol. 2011 Mar 3;147(2):335-6. doi: 10.1016/j.ijcard.2010.12.094. Epub 2011 Jan 20.
10
Vascular calcification in chronic renal failure: what have we learned from animal studies?慢性肾衰竭中的血管钙化：动物研究中我们学到了什么？
Circ Res. 2011 Jan 21;108(2):249-64. doi: 10.1161/CIRCRESAHA.110.225904.